Dr. Shepherd is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1 N Waukegan Rd
North Chicago, IL 60064Phone+1 314-454-6051Fax+1 314-454-6225- Is this information wrong?
Education & Training
- Washington University/B-JH/SLCH ConsortiumFellowship, Pediatric Endocrinology, 2005 - 2008
- Washington University/B-JH/SLCH ConsortiumResidency, Pediatrics, 2003 - 2005
- University of Illinois College of MedicineClass of 2003
Certifications & Licensure
- IL State Medical License 2008 - 2026
- CA State Medical License 2017 - 2025
- MO State Medical License 2008 - 2025
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Endocrinology
Clinical Trials
- Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor Start of enrollment: 2010 Mar 01
- Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2011 May 06
- Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer Start of enrollment: 2012 Jan 23
- Join now to see all
Publications & Presentations
PubMed
- 51 citations53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancerRachel M. Hurley, Andrea E. Wahner Hendrickson, Daniel W. Visscher, Peter Ansell, Maria I. Harrell, Jill M. Wagner, Vivian Negron, Krista M. Goergen, Matthew J. Maurer...> ;Gynecologic Oncology. 2019 Apr 1
- 60 citationsPhase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.Eve T. Rodler, Brenda F. Kurland, Melissa Griffin, Julie Gralow, Peggy L. Porter, Rosa F. Yeh, Vijayakrishna K. Gadi, Jamie Guenthoer, Jan H. Beumer, Larissa A. Korde,...> ;Clinical Cancer Research. 2016 Jan 22
- 9 citationsA phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancerDiane A.J. van der Biessen, Jourik A. Gietema, Maja J.A. de Jonge, Ingrid M.E. Desar, Martha W. den Hollander, Matthew W. Dudley, Martin Dunbar, Robert Hetman, Camille...> ;Investigational New Drugs. 2018 Jan 8
- Join now to see all
Press Mentions
- Fore Biotherapeutics Presents Positive Interim Data from Phase 1/2a Trial Evaluating FORE8394 in Patients with Advanced Tumors with Activating BRAF Alterations at ESMO 2022September 12th, 2022
- Chutes & Ladders—Another Novartis Exec Answers the Biotech Call, This Time for Gene Therapy Startup TevardMay 21st, 2021
- BioSpace Movers & Shakers, May 21May 20th, 2021
- Join now to see all
Hospital Affiliations
- UCSF Medical CenterSan Francisco, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: